ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
69.01
-0.08 (-0.12%)
At close: Aug 7, 2025, 4:00 PM
78.47
+9.46 (13.71%)
Pre-market: Aug 8, 2025, 8:38 AM EDT
ANI Pharmaceuticals Revenue
ANI Pharmaceuticals had revenue of $197.12M in the quarter ending March 31, 2025, with 43.43% growth. This brings the company's revenue in the last twelve months to $674.07M, up 30.26% year-over-year. In the year 2024, ANI Pharmaceuticals had annual revenue of $614.38M with 26.20% growth.
Revenue (ttm)
$674.07M
Revenue Growth
+30.26%
P/S Ratio
1.99
Revenue / Employee
$751,469
Employees
897
Market Cap
1.38B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 614.38M | 127.56M | 26.20% |
Dec 31, 2023 | 486.82M | 170.43M | 53.87% |
Dec 31, 2022 | 316.39M | 100.25M | 46.38% |
Dec 31, 2021 | 216.14M | 7.66M | 3.67% |
Dec 31, 2020 | 208.48M | 1.93M | 0.93% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ANIP News
- 1 hour ago - ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance - GlobeNewsWire
- 7 days ago - ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET - GlobeNewsWire
- 16 days ago - ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME) - GlobeNewsWire
- 5 weeks ago - ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th - GlobeNewsWire
- 2 months ago - ANI Pharmaceuticals Announces Presentation of New Preclinical Data - GlobeNewsWire
- 2 months ago - ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Benzinga
- 2 months ago - ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares - GlobeNewsWire